663 related articles for article (PubMed ID: 27760868)
41. Rituximab vs Ocrelizumab in Relapsing-Remitting Multiple Sclerosis.
Roos I; Hughes S; McDonnell G; Malpas CB; Sharmin S; Boz C; Alroughani R; Ozakbas S; Buzzard K; Skibina O; van der Walt A; Butzkueven H; Lechner-Scott J; Kuhle J; Terzi M; Laureys G; Van Hijfte L; John N; Grammond P; Grand'Maison F; Soysal A; Jensen AV; Rasmussen PV; Svendsen KB; Barzinji I; Nielsen HH; Sejbæk T; Prakash S; Stilund MLM; Weglewski A; Issa NM; Kant M; Sellebjerg F; Gray O; Magyari M; Kalincik T;
JAMA Neurol; 2023 Aug; 80(8):789-797. PubMed ID: 37307006
[TBL] [Abstract][Full Text] [Related]
42. Preferential spinal cord volume loss in primary progressive multiple sclerosis.
Tsagkas C; Magon S; Gaetano L; Pezold S; Naegelin Y; Amann M; Stippich C; Cattin P; Wuerfel J; Bieri O; Sprenger T; Kappos L; Parmar K
Mult Scler; 2019 Jun; 25(7):947-957. PubMed ID: 29781383
[TBL] [Abstract][Full Text] [Related]
43. Effectiveness and safety of Rituximab in multiple sclerosis: an observational study from Southern Switzerland.
Scotti B; Disanto G; Sacco R; Guigli M; Zecca C; Gobbi C
PLoS One; 2018; 13(5):e0197415. PubMed ID: 29758075
[TBL] [Abstract][Full Text] [Related]
44. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis.
Hauser SL; Waubant E; Arnold DL; Vollmer T; Antel J; Fox RJ; Bar-Or A; Panzara M; Sarkar N; Agarwal S; Langer-Gould A; Smith CH;
N Engl J Med; 2008 Feb; 358(7):676-88. PubMed ID: 18272891
[TBL] [Abstract][Full Text] [Related]
45. Clinical and fringe benefits of rituximab in multiple sclerosis treatment in a poor resource setting: Case series and cost analysis.
Aungsumart S; Apiwattanakul M
Mult Scler Relat Disord; 2023 May; 73():104673. PubMed ID: 37001410
[TBL] [Abstract][Full Text] [Related]
46. Modulation of Retinal Atrophy With Rituximab in Multiple Sclerosis.
Lambe J; Risher H; Filippatou AG; Murphy OC; Sotirchos ES; Ehrhardt H; Ogbuokiri E; Pellegrini N; Toliver B; Luciano NJ; Davis S; Fioravante N; Kwakyi O; Prince JL; Calabresi PA; Fitzgerald KC; Saidha S
Neurology; 2021 May; 96(20):e2525-e2533. PubMed ID: 33827962
[TBL] [Abstract][Full Text] [Related]
47. Simvastatin treatment in patients with relapsing-remitting multiple sclerosis receiving interferon beta 1a: a double-blind randomized controlled trial.
Togha M; Karvigh SA; Nabavi M; Moghadam NB; Harirchian MH; Sahraian MA; Enzevaei A; Nourian A; Ghanaati H; Firouznia K; Jannati A; Shekiba M
Mult Scler; 2010 Jul; 16(7):848-54. PubMed ID: 20488825
[TBL] [Abstract][Full Text] [Related]
48. Efficacy of alemtuzumab and natalizumab in the treatment of different stages of multiple sclerosis patients.
Wang L; Qi CH; Zhong R; Yuan C; Zhong QY
Medicine (Baltimore); 2018 Feb; 97(8):e9908. PubMed ID: 29465579
[TBL] [Abstract][Full Text] [Related]
49. Human placenta-derived cells (PDA-001) for the treatment of adults with multiple sclerosis: a randomized, placebo-controlled, multiple-dose study.
Lublin FD; Bowen JD; Huddlestone J; Kremenchutzky M; Carpenter A; Corboy JR; Freedman MS; Krupp L; Paulo C; Hariri RJ; Fischkoff SA
Mult Scler Relat Disord; 2014 Nov; 3(6):696-704. PubMed ID: 25891548
[TBL] [Abstract][Full Text] [Related]
50. Ocrelizumab treatment in multiple sclerosis: A Danish population-based cohort study.
Pontieri L; Blinkenberg M; Bramow S; Papp V; Rasmussen PV; Kant M; Schäfer J; Mathiesen HK; Jensen MB; Sirakov G; Berg JM; Kopp TI; Joensen H; Sellebjerg F; Magyari M
Eur J Neurol; 2022 Feb; 29(2):496-504. PubMed ID: 34644452
[TBL] [Abstract][Full Text] [Related]
51. Long-term B-lymphocyte depletion with rituximab in patients with relapsing-remitting multiple sclerosis.
Stüve O; Leussink VI; Fröhlich R; Hemmer B; Hartung HP; Menge T; Kieseier BC
Arch Neurol; 2009 Feb; 66(2):259-61. PubMed ID: 19204165
[TBL] [Abstract][Full Text] [Related]
52. Interrupting rituximab treatment in relapsing-remitting multiple sclerosis; no evidence of rebound disease activity.
Juto A; Fink K; Al Nimer F; Piehl F
Mult Scler Relat Disord; 2020 Jan; 37():101468. PubMed ID: 31683231
[TBL] [Abstract][Full Text] [Related]
53. How effective are disease-modifying drugs in delaying progression in relapsing-onset MS?
Brown MG; Kirby S; Skedgel C; Fisk JD; Murray TJ; Bhan V; Sketris IS
Neurology; 2007 Oct; 69(15):1498-507. PubMed ID: 17699802
[TBL] [Abstract][Full Text] [Related]
54. Association of Rituximab Treatment With Disability Progression Among Patients With Secondary Progressive Multiple Sclerosis.
Naegelin Y; Naegelin P; von Felten S; Lorscheider J; Sonder J; Uitdehaag BMJ; Scotti B; Zecca C; Gobbi C; Kappos L; Derfuss T
JAMA Neurol; 2019 Mar; 76(3):274-281. PubMed ID: 30615019
[TBL] [Abstract][Full Text] [Related]
55. Discontinuation and dose reduction of rituximab in relapsing-remitting multiple sclerosis.
Boremalm M; Sundström P; Salzer J
J Neurol; 2021 Jun; 268(6):2161-2168. PubMed ID: 33475825
[TBL] [Abstract][Full Text] [Related]
56. A phase 2, 24-week, randomized, placebo-controlled, double-blind study examining the efficacy and safety of an anti-interleukin-12 and -23 monoclonal antibody in patients with relapsing-remitting or secondary progressive multiple sclerosis.
Vollmer TL; Wynn DR; Alam MS; Valdes J
Mult Scler; 2011 Feb; 17(2):181-91. PubMed ID: 21135022
[TBL] [Abstract][Full Text] [Related]
57. Natalizumab Treatment for Relapsing-Remitting Multiple Sclerosis: The Experience From Saudi Arabia.
Algahtani H; Shirah B; Abobaker H; Alghanaim N; Kamel F
Clin Neuropharmacol; 2018; 41(6):199-201. PubMed ID: 30234558
[TBL] [Abstract][Full Text] [Related]
58. Rituximab versus fingolimod after natalizumab in multiple sclerosis patients.
Alping P; Frisell T; Novakova L; Islam-Jakobsson P; Salzer J; Björck A; Axelsson M; Malmeström C; Fink K; Lycke J; Svenningsson A; Piehl F
Ann Neurol; 2016 Jun; 79(6):950-8. PubMed ID: 27038238
[TBL] [Abstract][Full Text] [Related]
59. The role of endogenous antiradical protective system in multiple sclerosis.
Davitashvili D; Beridze M; Shakarishvili R; Kiziria M; Sanikidze T
Georgian Med News; 2012 Apr; (205):11-9. PubMed ID: 22665726
[TBL] [Abstract][Full Text] [Related]
60. Sustained Low Relapse Rate With Highly Variable B-Cell Repopulation Dynamics With Extended Rituximab Dosing Intervals in Multiple Sclerosis.
Starvaggi Cucuzza C; Longinetti E; Ruffin N; Evertsson B; Kockum I; Jagodic M; Al Nimer F; Frisell T; Piehl F
Neurol Neuroimmunol Neuroinflamm; 2023 Jan; 10(1):. PubMed ID: 36411076
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
